Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.48 |
| ▸ | CA9 | Q16790 | 5/20 | 0.48 |
| ▸ | CA12 | O43570 | 4/20 | 0.48 |
| ▸ | CA1 | P00915 | 4/20 | 0.48 |
| ▸ | MMP12 | P39900 | 2/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18241575 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL19772702 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL17235369 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL20348905 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL15334243 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL24807806 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL19572694 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL18513238 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL22927913 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 | |
| SCHEMBL26707084 | 1.00 | LMNA (0.64) | LMNAKMT2APOLBALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328310-A1 | SIRNA TARGETING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 AND SIRNA CONJUGATE | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20230355775-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-11-02 | — | — | US | disclosed |
| EP-4269400-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Molecure SA (PL) | 2023-11-01 | — | — | EP | disclosed |
| US-20230220384-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-07-13 | — | — | US | disclosed |
| US-20230193277-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-06-22 | — | — | US | disclosed |
| EP-4194553-A1 | MODIFIED SIRNA WITH REDUCED OFF-TARGET ACTIVITY | Tuojie Biotech (Shanghai) Co., Ltd. (CN) | 2023-06-14 | — | — | EP | disclosed |
| US-11660347-B2 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-05-30 | — | — | US | disclosed |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230132756-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF | Suzhou Ribo Life Science Co., Ltd. (CN) | 2023-05-04 | — | — | US | disclosed |
| EP-3718572-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2020-10-07 | — | — | EP | disclosed |
| EP-3719127-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE | Suzhou Ribo Life Science Co., Ltd. (CN) | 2020-10-07 | — | — | EP | disclosed |
| US-10793862-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2020-10-06 | — | — | US | disclosed |
| WO-2020135581-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州瑞博生物技术有限公司 | 2020-07-02 | — | — | WO | disclosed |
| WO-2020135673-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州瑞博生物技术有限公司 | 2020-07-02 | — | — | WO | disclosed |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | IONIS PHARMACEUTICALS, INC. (US) | 2020-05-21 | — | — | US | disclosed |
| WO-2020038377-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION AND CONJUGATE CONTAINING NUCLEIC ACID, AND USE THEREOF | 苏州瑞博生物技术有限公司 | 2020-02-27 | — | — | WO | disclosed |
| US-20190055554-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2019-02-21 | — | — | US | disclosed |
| US-9994855-B2 | Compositions and methods for modulating growth hormone receptor expression | IONIS PHARMACEUTICALS, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170166899-A1 | COMPOSITIONS AND METHODS FOR MODULATING GROWTH HORMONE RECEPTOR EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190055554-A1 | COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION | HAVCR2, HCCS, HDGF | LMNA 823/4885KMT2A 2874/4885POLB 1047/4885 |
| US-20230348516-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | LMNA 2274/4885KMT2A 2797/4885POLB 4405/4885 |
| US-11660347-B2 | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof | APOB, C1QBP, APOL1 | LMNA 301/4885KMT2A 1671/4885POLB 184/4885 |
| US-20230193277-A1 | NUCLEIC ACID, PHARMACEUTICAL COMPOSITION, CONJUGATE, PREPARATION METHOD, AND USE | F13A1, F13B, F11 | LMNA 91/4885KMT2A 1302/4885POLB 195/4885 |
| US-20230355775-A1 | NUCLEIC ACID, COMPOSITION AND CONJUGATE CONTAINING SAME, PREPARATION METHOD, AND USE THEREOF | APOB, C1QBP, APOL1 | LMNA 301/4885KMT2A 1671/4885POLB 184/4885 |
| US-20230132756-A1 | DOUBLE-STRANDED OLIGONUCLEOTIDE, COMPOSITION AND CONJUGATE COMPRISING DOUBLE-STRANDED OLIGONUCLEOTIDE, PREPARATION METHOD THEREOF AND USE THEREOF | POLN, POLM, DUT | LMNA 803/4885KMT2A 2025/4885POLB 22/4885 |
| US-20200157548-A1 | COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS | SI, FABP2, GNE | LMNA 703/4885KMT2A 3802/4885POLB 3519/4885 |
| US-20230151365-A1 | COMPOSITIONS AND METHODS FOR MODULATING TTR EXPRESSION | TTR, GALNT1, GALNT3 | LMNA 885/4885KMT2A 3611/4885POLB 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.